BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 25479686)

  • 1. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.
    Izzo F; Mercogliano F; Venturutti L; Tkach M; Inurrigarro G; Schillaci R; Cerchietti L; Elizalde PV; Proietti CJ
    Breast Cancer Res; 2014 Dec; 16(6):491. PubMed ID: 25479686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
    Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
    Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.
    Pierson-Mullany LK; Lange CA
    Mol Cell Biol; 2004 Dec; 24(24):10542-57. PubMed ID: 15572662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases.
    Skildum A; Faivre E; Lange CA
    Mol Endocrinol; 2005 Feb; 19(2):327-39. PubMed ID: 15486045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
    Giulianelli S; Vaqué JP; Soldati R; Wargon V; Vanzulli SI; Martins R; Zeitlin E; Molinolo AA; Helguero LA; Lamb CA; Gutkind JS; Lanari C
    Cancer Res; 2012 May; 72(9):2416-27. PubMed ID: 22396492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
    Carnevale RP; Proietti CJ; Salatino M; Urtreger A; Peluffo G; Edwards DP; Boonyaratanakornkit V; Charreau EH; Bal de Kier Joffé E; Schillaci R; Elizalde PV
    Mol Endocrinol; 2007 Jun; 21(6):1335-58. PubMed ID: 17440047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators.
    Faivre E; Skildum A; Pierson-Mullany L; Lange CA
    Steroids; 2005; 70(5-7):418-26. PubMed ID: 15862825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone.
    Gizard F; Robillard R; Gross B; Barbier O; Révillion F; Peyrat JP; Torpier G; Hum DW; Staels B
    Mol Cell Biol; 2006 Oct; 26(20):7632-44. PubMed ID: 17015480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
    Liang Y; Wu J; Stancel GM; Hyder SM
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2.
    Diaz Flaqué MC; Vicario R; Proietti CJ; Izzo F; Schillaci R; Elizalde PV
    Steroids; 2013 Jun; 78(6):559-67. PubMed ID: 23178160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor.
    McGowan EM; Russell AJ; Boonyaratanakornkit V; Saunders DN; Lehrbach GM; Sergio CM; Musgrove EA; Edwards DP; Sutherland RL
    Cancer Res; 2007 Sep; 67(18):8942-51. PubMed ID: 17875737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth.
    Daniel AR; Qiu M; Faivre EJ; Ostrander JH; Skildum A; Lange CA
    Steroids; 2007 Feb; 72(2):188-201. PubMed ID: 17173941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.
    Shan L; Li X; Liu L; Ding X; Wang Q; Zheng Y; Duan Y; Xuan C; Wang Y; Yang F; Shang Y; Shi L
    Oncogene; 2014 Jun; 33(24):3205-16. PubMed ID: 23851505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation.
    Salatino M; Beguelin W; Peters MG; Carnevale R; Proietti CJ; Galigniana MD; Vedoy CG; Schillaci R; Charreau EH; Sogayar MC; Elizalde PV
    Oncogene; 2006 Dec; 25(59):7723-39. PubMed ID: 16799639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of mitogen- and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins.
    Reyes D; Ballaré C; Castellano G; Soronellas D; Bagó JR; Blanco J; Beato M
    Oncogene; 2014 Mar; 33(12):1570-80. PubMed ID: 23604116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells.
    Daniel AR; Faivre EJ; Lange CA
    Mol Endocrinol; 2007 Dec; 21(12):2890-906. PubMed ID: 17717077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming.
    Diep CH; Knutson TP; Lange CA
    Mol Cancer Res; 2016 Feb; 14(2):141-62. PubMed ID: 26577046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells.
    Wu J; Brandt S; Hyder SM
    Mol Endocrinol; 2005 Feb; 19(2):312-26. PubMed ID: 15528272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells.
    McGowan EM; Clarke CL
    Mol Endocrinol; 1999 Oct; 13(10):1657-71. PubMed ID: 10517668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.